ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Vyndaqel 61 mg, Weichkapseln - 30
67518001 Pfizer AG
Vyndaqel 61 mg, Weichkapseln05.03.2020
  05.03.2020
Tafamidis (N07XX08) 
WHO-DDD 
01.99.30
01.99. 
B  
Yes 
IPCI
9422.28Yes
    
10 %9975.05
7680675180011Synthetika
  
Composition
tafamidisum 61 mg, macrogolum 400, polysorbatum 20, povidonum K 90, E 321, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (rubrum), Drucktinte: macrogolum 400, polyvinylis acetas phtalas, E 171, propylenglycolum, pro capsula.
Packungsbestandteile
Soft capsules 
 
Active AgentDose
Tafamidisum61 mg
BAG: Active AgentDose
Tafamidisum61 mg
 
Inactive agentsDoseadditional_information
(Rubrum)  
E 171 color.
E 172 color.
E 321  
Gelatina Kapselhülle
Glycerol  
Macrogol400 Drucktinte
Polysorbatum 20  
Polyvinylis Acetas Phtalas  
Povidonum K90  
Pro Capsula  
Propylenglycol  
Sorbitolum Liquidum Partim Deshydricum  
 
Source
Data was imported : 07.08.2024 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home